ELDN — Eledon Pharmaceuticals Cashflow Statement
0.000.00%
- $235.14m
- $157.50m
Annual cashflow statement for Eledon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -34.5 | -88 | -40.3 | -36.2 | -45.6 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 8.1 | 57.2 | 5.72 | -20.2 | -24.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.152 | 2.37 | -4.92 | 8.71 | 7.65 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -28.9 | -28.4 | -39.5 | -47.3 | -62.3 |
| Other Investing Cash Flow Items | 0 | — | -45.3 | -70.3 | 10.8 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | — | -45.3 | -70.3 | 10.8 |
| Financing Cash Flow Items | -0.45 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -0.449 | 0 | 33 | 134 | 53.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -29.4 | -28.4 | -51.8 | 15.9 | 2.26 |